Measuring Beta-galactose Exposure on Platelets: Standardization and Healthy Reference Values
Overview
Authors
Affiliations
Background: Correct diagnosis of the cause of thrombocytopenia is crucial for the appropriate management of patients. Hyposialylation/desialylation (characterized by abnormally high β-galactose exposure) accelerates platelet clearance and can lead to thrombocytopenia. However, the reference range for β-galactose exposure in healthy individuals has not been defined previously.
Objective: The objective of the present study was to develop a standardized assay of platelet β-galactose exposure for implementation in a clinical laboratory.
Methods: β-Galactose exposure was measured in platelet-rich plasma by using flow cytometry and agglutinin (RCA). A population of 120 healthy adults was recruited to study variability.
Results: We determined an optimal RCA concentration of 12.5 μg/mL. The measure was stable for up to 4 hours (mean fluorescence intensity [MFI]-RCA: 1233 ± 329 at 0 hour and 1480 ± 410 at 4 hours). The platelet count did not induce a variation of RCA and the measure of RCA was stable when tested up to 24 hours after blood collection (MFI-RCA: 1252 ± 434 at day 0 and 1140 ± 297 24 hours after blood sampling). To take into account the platelet size, results should be expressed as RCA/forward scatter ratio. We used the assay to study variability in 120 healthy adults, and we found that the ratio is independent of sex and blood group.
Conclusion: We defined a normal range in a healthy population and several preanalytical and analytical variables were evaluated, together with positive and negative controls. This assay may assist in the diagnosis of thrombocytopenic diseases linked to changes in β-galactose exposure.
Postic G, Solarz J, Loubiere C, Kandiah J, Sawmynaden J, Adam F J Cell Mol Med. 2023; 27(15):2228-2238.
PMID: 37415307 PMC: 10399536. DOI: 10.1111/jcmm.17817.
Characterization of the human platelet N- and O-glycome upon storage using tandem mass spectrometry.
Rosenbalm K, Lee-Sundlov M, Ashline D, Grozovsky R, Aoki K, Hanneman A Blood Adv. 2023; 7(16):4278-4290.
PMID: 36952551 PMC: 10424148. DOI: 10.1182/bloodadvances.2022007084.
DNA Origami-Platelet Adducts: Nanoconstruct Binding without Platelet Activation.
Roka-Moiia Y, Walawalkar V, Liu Y, Italiano J, Slepian M, Taylor R Bioconjug Chem. 2022; 33(7):1295-1310.
PMID: 35731951 PMC: 9463463. DOI: 10.1021/acs.bioconjchem.2c00197.
Chen Y, Luo L, Zheng Y, Zheng Q, Zhang N, Gan D Front Immunol. 2022; 13:810620.
PMID: 35450072 PMC: 9016750. DOI: 10.3389/fimmu.2022.810620.
Measuring beta-galactose exposure on platelets: Standardization and healthy reference values.
Lasne D, Pascreau T, Darame S, Bourrienne M, Tournoux P, Philippe A Res Pract Thromb Haemost. 2020; 4(5):813-822.
PMID: 33134771 PMC: 7586713. DOI: 10.1002/rth2.12369.